UNDERSTANDING AND TARGETING ACQUIRED CHEMORESISTANCE IN HIGH-GRADE SEROUS OVARIAN CANCER
Grant number: 1124309 | Funding period: 2017 - 2019
We recently discovered a mutation in recurrent high-grade serous ovarian cancer that causes profound overexpression of the multidrug resistance pump, MDR1 (Patch et al Nature 2015). In this study I will explore approaches to reverse drug resistance caused by this mutation in recurrent ovarian cancer with a view to utilising alternative treatments to improve patient outcomes.
Related publications (7)
Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.
Nikki L Burdett, Madelynne O Willis, Kathryn Alsop, Allison L Hunt, Ahwan Pandey, Phineas T Hamilton, Tamara Abulez, Xuan Liu, Therese Hoang, Stuart Craig, Sian Fereday, Joy Hendley, Dale W Garsed, Katy Milne, Shreena Kalaria, Ashley Marshall, Brian L Hood, Katlin N Wilson, Kelly A Conrads, Kathleen I Pishas
High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and, wh..
Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer
Kathleen Pishas, Karla J Cowley, Ahwan Pandey, Therese Hoang, Jessica A Beach, Jennii Luu, Robert Vary, Lorey K Smith, Carolyn E Shembrey, Nineveh Rashoo, Madelynne O White, Kaylene J Simpson, Andrea Bild, Jason Griffiths, Dane Cheasley, Ian Campbell, David DL Bowtell, Elizabeth L Christie
Despite high response rates to initial chemotherapy, the majority of women diagnosed with High-Grade Serous Ovarian Cancer (HGSOC)..
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.
Aritro Nath, Patrick Cosgrove, Benjamin Copeland, Hoda Mirsafian, Elizabeth Christie, Lance Pflieger, Sumana Majumdar, Mihaela Cristea, Ernest Han, Stephen Lee, Edward Wang, Sian Fereday, Nadia Traficante, Ravi Salgia, Theresa Werner, Adam Cohen, Phillip Moos, Jeffrey Chang, David Bowtell, Andrea Bild
The evolution of resistance in high-grade serous ovarian cancer (HGSOC) cells following chemotherapy is only partially understood...
The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer
EL Christie, AE Freimund, S Fereday, K Alsop, T Hoang, K Pishas, G Au-Yeung, M Friedlander, DD Bowtell
BRCA1 and BRCA2 tumor suppressor genes are central components of the homologous recombination (HR) DNA repair pathway, a high-fide..
Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer
Elizabeth H Stover, Maria B Baco, Ofir Cohen, Yvonne Y Li, Elizabeth L Christie, Mukta Bagul, Amy Goodale, Yenarae Lee, Sasha Pantel, Matthew G Rees, Guo Wei, Adam G Presser, Maya K Gelbard, Weiqun Zhang, Ioannis K Zervantonakis, Patrick D Bhola, Jeremy Ryan, Jennifer L Guerriero, Joan Montero, Felice J Liang
High-grade serous ovarian cancer (HGSOC) is often sensitive to initial treatment with platinum and taxane combination chemotherapy..
Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer
Elizabeth L Christie, Swetansu Pattnaik, Jessica Beach, Anthony Copeland, Nineveh Rashoo, Sian Fereday, Joy Hendley, Kathryn Alsop, Samuel L Brady, Greg Lamb, Ahwan Pandey, Anna deFazio, Heather Thorne, Andrea Bild, David DL Bowtell
ABCB1 encodes Multidrug Resistance protein (MDR1), an ATP-binding cassette member involved in the cellular efflux of chemotherapeu..